The development of multitarget-directed ligands (MTDLs) has become a widely focused
research topic, but rational design remains as an enormous challenge. This paper reviews …

Despite enormous progress in the treatment of many malignancies, the development of
cancer resistance is still an important reason for cancer chemotherapy failure. Increasing …

The dominant paradigm in drug discovery is to design ligands with maximum selectivity to
act on individual drug targets. With the target-based approach, many new chemical entities …

Despite the encouraging clinical progress of chemotherapeutic agents in cancer treatment,
innovation and development of new effective anticancer candidates still represents a …

Histone deacetylases (HDACs), encompassing at least 18 members, are promising targets
for anticancer drug discovery and development. To date, five histone deacetylase inhibitors …

CUDC-907 is a first-in-class, oral small molecule inhibitor of both HDAC (class I and II) and
PI3K (class Iα, β, and δ) enzymes, with demonstrated anti-tumor activity in multiple pre …

Cancer comprises a heterogeneous disease, characterized by diverse features such as
constitutive expression of oncogenes and/or downregulation of tumor suppressor genes …

The landscape of head and neck squamous cell carcinoma (HNSCC) has been changing
rapidly due to growing proportion of HPV-related disease and development of new …

Aberrant chromatin remodeling and activation of the PI3K pathway have been identified as
important mediators of pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine …

Background Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with an
appalling overall survival of less than 5%(Zimmerman et al. J Thor Oncol 14: 768-83, 2019) …